January 29, 2026
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
Pharmaceuticals, Biotechnology and Life Sciences
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to…
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by…
OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the…
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly…
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth…
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…